Coverage
-
September 22, 2022
A West Virginia federal judge has found that Mylan Pharmaceuticals Inc.'s planned generics of a pair of multibillion-dollar-selling diabetes drugs sold by Merck & Co. Inc. would infringe Merck's patents on the products.
2 other articles on this case.
View all »